23,428 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 23,428 shares of the biopharmaceutical company's stock, valued at approximately $705,000.

Several other institutional investors also recently modified their holdings of the business. Blue Trust Inc. raised its position in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC purchased a new position in shares of TG Therapeutics in the 4th quarter worth $75,000. Finally, GAMMA Investing LLC grew its stake in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 2,171 shares during the period. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on TGTX. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Remove Ads

TG Therapeutics Price Performance

Shares of TGTX stock traded up $0.73 during mid-day trading on Friday, hitting $36.71. The company had a trading volume of 2,052,937 shares, compared to its average volume of 3,110,585. The company has a market capitalization of $5.77 billion, a P/E ratio of -367.06 and a beta of 2.14. The stock's 50 day moving average price is $35.76 and its 200-day moving average price is $31.39. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.